DE69706748D1 - Oral anzuwendende Matrixtabletten mit verzögerter Wirkstoffabgabe enthaltend Tianeptin Natriumsalz - Google Patents

Oral anzuwendende Matrixtabletten mit verzögerter Wirkstoffabgabe enthaltend Tianeptin Natriumsalz

Info

Publication number
DE69706748D1
DE69706748D1 DE69706748T DE69706748T DE69706748D1 DE 69706748 D1 DE69706748 D1 DE 69706748D1 DE 69706748 T DE69706748 T DE 69706748T DE 69706748 T DE69706748 T DE 69706748T DE 69706748 D1 DE69706748 D1 DE 69706748D1
Authority
DE
Germany
Prior art keywords
active ingredient
sodium salt
delayed release
ingredient containing
matrix tablets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69706748T
Other languages
English (en)
Other versions
DE69706748T2 (de
Inventor
De Barochez Bruno Huet
Patrick Wuthrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Original Assignee
ADIR SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADIR SARL filed Critical ADIR SARL
Publication of DE69706748D1 publication Critical patent/DE69706748D1/de
Application granted granted Critical
Publication of DE69706748T2 publication Critical patent/DE69706748T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
DE69706748T 1996-04-24 1997-04-23 Oral anzuwendende Matrixtabletten mit verzögerter Wirkstoffabgabe enthaltend Tianeptin Natriumsalz Expired - Lifetime DE69706748T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9605174A FR2747921B1 (fr) 1996-04-24 1996-04-24 Comprime matriciel permettant la liberation prolongee du sel de sodium de tianeptine apres administration par voie orale

Publications (2)

Publication Number Publication Date
DE69706748D1 true DE69706748D1 (de) 2001-10-25
DE69706748T2 DE69706748T2 (de) 2002-07-04

Family

ID=9491549

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69706748T Expired - Lifetime DE69706748T2 (de) 1996-04-24 1997-04-23 Oral anzuwendende Matrixtabletten mit verzögerter Wirkstoffabgabe enthaltend Tianeptin Natriumsalz

Country Status (18)

Country Link
US (1) US5888542A (de)
EP (1) EP0803253B1 (de)
JP (1) JPH1036268A (de)
CN (1) CN1116029C (de)
AT (1) ATE205715T1 (de)
AU (1) AU719822B2 (de)
CA (1) CA2203310C (de)
DE (1) DE69706748T2 (de)
DK (1) DK0803253T3 (de)
ES (1) ES2164310T3 (de)
FR (1) FR2747921B1 (de)
GR (1) GR3037043T3 (de)
HU (1) HU224192B1 (de)
NO (1) NO315407B1 (de)
NZ (1) NZ314662A (de)
PL (1) PL188135B1 (de)
PT (1) PT803253E (de)
ZA (1) ZA973495B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2791891A1 (fr) * 1999-04-07 2000-10-13 Adir Utilisation de la tianeptine pour l'obtention de medicaments destines au traitement des pathologies de la neurodegenerescence
US6683072B1 (en) 2003-02-04 2004-01-27 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of irritable bowel syndrome and nonulcer dyspepsia
ATE454138T1 (de) * 2003-08-08 2010-01-15 Biovail Lab Int Srl Tablette mit modifizierter freisetzung von bupropion hydrochlorid
US20050227961A1 (en) * 2004-04-08 2005-10-13 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
US9314469B2 (en) 2008-05-05 2016-04-19 Tonix Pharma Holdings Limited Method for treating neurocognitive dysfunction
US8198268B2 (en) 2008-10-31 2012-06-12 Janssen Biotech, Inc. Tianeptine sulfate salt forms and methods of making and using the same
US20110237537A1 (en) * 2009-05-29 2011-09-29 Lombard Jay L Methods for assessment and treatment of mood disorders via single nucleotide polymorphisms analysis
US20100304391A1 (en) * 2009-05-29 2010-12-02 Lombard Jay L Methods for assessment and treatment of depression via utilization of single nucleotide polymorphisms analysis
US8355927B2 (en) 2010-11-05 2013-01-15 Genomind, Llc Neuropsychiatric test reports
KR20120092993A (ko) * 2011-02-14 2012-08-22 지엘팜텍 주식회사 티아넵틴 또는 이의 약제학적으로 허용되는 염을 포함하는 경구투여용 서방성 정제
EP2561864B1 (de) * 2011-08-25 2014-12-31 Zaklady Farmaceutyczne Polpharma SA Beschichtete Tablette mit Tianeptin und Verfahren zu deren Herstellung
KR101136976B1 (ko) * 2011-09-06 2012-05-30 건일제약 주식회사 티아넵틴 또는 그의 염을 포함하는 탈모증의 예방 또는 치료용 약학 조성물
GB201208315D0 (en) 2012-05-11 2012-06-27 Numedicus Ltd Pharmaceutical methods and compositions
CN104031005B (zh) * 2014-05-30 2016-04-27 济南诚汇双达化工有限公司 一种噻萘普汀钠中间体的制备方法
KR20180101307A (ko) 2018-09-04 2018-09-12 지엘팜텍주식회사 티아넵틴 또는 이의 약제학적으로 허용되는 염을 포함하는 경구투여용 서방성 정제
KR20200104265A (ko) 2020-08-21 2020-09-03 지엘팜텍주식회사 티아넵틴 또는 이의 약제학적으로 허용되는 염을 포함하는 경구투여용 서방성 정제

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5446070A (en) * 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
FR2635461B1 (fr) * 1988-08-18 1992-01-17 Adir Utilisation de derives tricycliques pour l'obtention de medicaments destines au traitement du stress
FR2716623B1 (fr) * 1994-02-25 1996-08-23 Adir Utilisation d'un dérivé tricyclique pour l'obtention de médicaments destinés au traitement des troubles mnémo-cognitifs.

Also Published As

Publication number Publication date
HUP9700806A3 (en) 2000-01-28
FR2747921B1 (fr) 1998-10-30
PT803253E (pt) 2001-12-28
HU224192B1 (hu) 2005-06-28
ATE205715T1 (de) 2001-10-15
CN1168792A (zh) 1997-12-31
PL319627A1 (en) 1997-10-27
US5888542A (en) 1999-03-30
EP0803253B1 (de) 2001-09-19
NO971860D0 (no) 1997-04-23
EP0803253A1 (de) 1997-10-29
CA2203310A1 (fr) 1997-10-24
AU719822B2 (en) 2000-05-18
AU1904197A (en) 1997-10-30
NO971860L (no) 1997-10-27
HUP9700806A2 (hu) 1998-10-28
ZA973495B (en) 1997-11-18
GR3037043T3 (en) 2002-01-31
NO315407B1 (no) 2003-09-01
DK0803253T3 (da) 2001-11-19
HU9700806D0 (en) 1997-06-30
NZ314662A (en) 1998-12-23
JPH1036268A (ja) 1998-02-10
ES2164310T3 (es) 2002-02-16
FR2747921A1 (fr) 1997-10-31
CA2203310C (fr) 2001-10-23
DE69706748T2 (de) 2002-07-04
CN1116029C (zh) 2003-07-30
PL188135B1 (pl) 2004-12-31

Similar Documents

Publication Publication Date Title
DE69706748T2 (de) Oral anzuwendende Matrixtabletten mit verzögerter Wirkstoffabgabe enthaltend Tianeptin Natriumsalz
FI944035A0 (fi) Tramadolisuolaa sisältävä lääkeaine, jolla on viivästynyt vaikuttavan aineen vapautuminen
BR9917012A (pt) Comprimido matricial, permitindo a liberação prolongada de gliclazida, após administração por via oral
TWI235068B (en) Sustained-release pharmaceutical composition
PT781550E (pt) Composicao farmaceutica bioadesiva para a libertacao controlada de principios activos
ATE200864T1 (de) Tablette mit gesteuerter freisetzung von alfuzosinhydrochlorid
NO20065390L (no) Farmasoytisk preparat i fast enhetsdoseringsform
ZA959367B (en) Melt-extrusion multiparticulates
DK1375503T3 (da) Dioxinoderivater og deres anvendelse som dopaminagonister
NO983544D0 (no) Implanterbart system med varig avgivelse av et biologisk aktivt middel
PT1037614E (pt) Uma capsula dupla para a administracao de principios activos em terapeuticas multiplas
HUP9602601A3 (en) Piperidine and piperazine derivatives, medicines containing them as active ingredient and their use
AU651894B2 (en) Matrix tablet permitting the sustained release of indapamide after oral administration
ES2077757T5 (es) Preparacion farmaceutica solida con disolucion rapida que contiene la n-acetilcisteina.
DE69625189D1 (de) Tablette mit gesteuerter freisetzung
DE69118081T2 (de) Hyaluronsäurenatriumsalz und Desinfektionsmittel enthaltende pharmazeutische Zusammensetzungen zur äusserlichen Anwendung
DE59804823D1 (de) Arzneimittelformulierung mit kontrollierter wirkstofffreisetzung
NZ504418A (en) Delayed release oral dosage form of carvedilol
NO20020987L (no) Naturlig, fysiologisk aktivt stoff som er virksomt mot fiske- parasittisme, og fiskefôr inneholdende stoffet
PT806202E (pt) Composicao farmaceutica a base de matrizes lipofilas estabilizadas para a libertacao controlada de principios activos
FR2745500B1 (fr) Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine
DK0948961T3 (da) Calciumholdig brusetablet med et antihistaminikum som aktivt stof
HUP0002459A3 (en) Salts of optically active sulfoxide derivative, pharmaceutical compositions containing them and use thereof

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: LES LABORATOIRES SERVIER, NEUILLY-SUR-SEINE, FR

8364 No opposition during term of opposition